Garcia-Padilla Carlos, Lozano-Velasco Estefanía, Garcia-Lopez Virginio, Aranega Amelia, Franco Diego, Garcia-Martinez Virginio, Lopez-Sanchez Carmen
Department of Human Anatomy and Embryology, Faculty of Medicine, Institute of Molecular Pathology Biomarkers, University of Extremadura, 06006 Badajoz, Spain.
Department of Experimental Biology, University of Jaen, 23071 Jaen, Spain.
Biomedicines. 2022 Nov 30;10(12):3076. doi: 10.3390/biomedicines10123076.
Heart failure constitutes a clinical complex syndrome with different symptomatic characteristics depending on age, sex, race and ethnicity, among others, which has become a major public health issue with an increasing prevalence. One of the most interesting tools seeking to improve prevention, diagnosis, treatment and prognosis of this pathology has focused on finding new molecular biomarkers since heart failure relies on deficient cardiac homeostasis, which is regulated by a strict gene expression. Therefore, currently, analyses of non-coding RNA transcriptomics have been oriented towards human samples. The present review develops a comparative study emphasizing the relevance of microRNAs, long non-coding RNAs and circular RNAs as potential biomarkers in heart failure. Significantly, further studies in this field of research are fundamental to supporting their widespread clinical use. In this sense, the various methodologies used by the authors should be standardized, including larger cohorts, homogeneity of the samples and uniformity of the bioinformatic pipelines used to reach stratification and statistical significance of the results. These basic adjustments could provide promising steps to designing novel strategies for clinical management of patients with heart failure.
心力衰竭是一种临床综合征,具有不同的症状特征,这些特征取决于年龄、性别、种族和民族等因素,随着患病率的增加,它已成为一个重大的公共卫生问题。由于心力衰竭依赖于由严格基因表达调控的心脏内环境稳态不足,因此寻求改善这种疾病的预防、诊断、治疗和预后的最有趣工具之一,集中在寻找新的分子生物标志物上。因此,目前非编码RNA转录组学分析主要针对人类样本。本综述开展了一项比较研究,强调了微小RNA、长链非编码RNA和环状RNA作为心力衰竭潜在生物标志物的相关性。值得注意的是,该研究领域的进一步研究对于支持它们在临床上的广泛应用至关重要。从这个意义上说,作者使用的各种方法应该标准化,包括更大的队列、样本的同质性以及用于实现结果分层和统计学意义的生物信息学管道的一致性。这些基本调整可以为设计心力衰竭患者临床管理的新策略提供有前景的步骤。
Biomedicines. 2022-11-30
Eur J Heart Fail. 2017-3-27
J Physiol. 2017-6-15
ESC Heart Fail. 2015-9
Cells. 2020-5-17
Front Cardiovasc Med. 2020-11-23
Circulation. 2020-1-27
J Cardiovasc Dev Dis. 2023-10-24
J Cardiovasc Dev Dis. 2023-3-15
Arch Med Sci. 2021-3-10
Int J Mol Sci. 2022-7-27
Front Oncol. 2022-7-22
Basic Res Cardiol. 2022-6-23